Exelixis Inc Restricted Cash and Cash Equivalents
Exelixis Inc (EXEL) had Restricted Cash and Cash Equivalents of $0 as of 2023-12-29, per its 10-K filed 2024-02-06.
Discontinued › Balance Sheet › Assets
us-gaap:RestrictedCashAndCashEquivalents · last filed 2024-02-06
- 2023-12-29: Restricted Cash and Cash Equivalents $0.00.
- 2023-09-29: Restricted Cash and Cash Equivalents $0.00.
- 2023-06-30: Restricted Cash and Cash Equivalents $0.00.
| Period end | Restricted Cash and Cash Equivalents |
|---|---|
| 2023-12-29 | $0.00 10-K · filed 2024-02-06 |
| 2023-09-29 | $0.00 10-Q · filed 2023-11-01 |
| 2023-06-30 | $0.00 10-Q · filed 2023-08-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |